Huber Reid M 4

What Happened
Reid M. Huber, a director of Rapport Therapeutics, was granted a derivative award covering 15,200 shares, reported on Form 4 dated June 10, 2026. The filing lists the transaction as an award/acquisition (code A) with a reported price of $0.00 (derivative security). This is a compensatory award to a director, not an open‑market purchase or sale, and does not reflect an immediate cash outlay or sale.

Key Details

• Transaction date: 2026-06-10 (filed same day).
• Security: Derivative award covering 15,200 shares; price reported as $0.00.
• Vesting: Shares underlying the option vest on the earlier of (i) June 10, 2027 or (ii) the date of the next Annual Meeting, subject to continued service (footnote).
• Shares owned after transaction: Not specified in this Form 4.
• Timeliness: Filed on the same date as the transaction (timely).
• Transaction code: A = Award/Grant (derivative).

Context
This grant appears to be a compensatory option/award to a director that vests over time; the filing does not show an immediate exercise or sale of shares. Such awards are common as part of director compensation and should not be read alone as a direct market bet by the insider. For full terms (exercise price, expiration, and other conditions) check the company’s proxy, equity award agreements, or subsequent filings.